Logo-bi
Bioimpacts. 2020;10(3): 205-206. doi: 10.34172/bi.2020.25
PMID: 32793443        PMCID: PMC7416005

Letter to the Editor

Computational-based drug repurposing methods in COVID-19

Yosef Masoudi-Sobhanzadeh 1 * ORCID

Cited by CrossRef: 19

1- Kumar A, Kumar D, Kumar R, Singh P, Chandra R, Kumari K. DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2. Journal of Biomolecular Structure and Dynamics. 2022;40(6):2600 [Crossref]
2- Ranjan P, Chakraborty T. Computational insight of repurpose drug for treatment of COVID-19: a CDFT approach. Theor Chem Acc. 2024;143(1) [Crossref]
3- Ranjan P, Gaurav K, Chakraborty T. Computational study of some potential inhibitors of COVID‐19: A DFT analysis. Quant Biol. 2022;10(4):341 [Crossref]
4- Masoudi-Sobhanzadeh Y, Salemi A, Pourseif M, Jafari B, Omidi Y, Masoudi-Nejad A. Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries. 2021;22(6) [Crossref]
5- Arabi Bulaghi Z, Habibizad Navin A, Hosseinzadeh M, Rezaee A. World competitive contest-based artificial neural network: A new class-specific method for classification of clinical and biological datasets. Genomics. 2021;113(1):541 [Crossref]
6- Hooshmand S, Zarei Ghobadi M, Hooshmand S, Azimzadeh Jamalkandi S, Alavi S, Masoudi-Nejad A. A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. Mol Divers. 2021;25(3):1717 [Crossref]
7- Urakov A, Urakova N, Yagudin I, Svetova M, Suntsova D. COVID-19: Artificial sputum, respiratory obstruction method and screening of pyolitic and antihypoxic drugs. Bioimpacts. 2022;12(4):393 [Crossref]
8- Masoudi-Sobhanzadeh Y, Esmaeili H, Masoudi-Nejad A. A fuzzy logic-based computational method for the repurposing of drugs against COVID-19. Bioimpacts. 2022;12(4):315 [Crossref]
9- Singh D, Singh A, Chawla P. An overview of current strategies and future prospects in drug repurposing in tuberculosis. 2023;:71 [Crossref]
10- Mohanty S, Rashid M, Mohanty C, Swayamsiddha S. Modern computational intelligence based drug repurposing for diabetes epidemic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2021;15(4):102180 [Crossref]
11- Tian X, Shen L, Gao P, Huang L, Liu G, Zhou L, Peng L. Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization With Kernel Diffusion. Front Microbiol. 2022;13 [Crossref]
12- Ibrahim I, Elfiky A, Elgohary A. Recognition through GRP78 is enhanced in the UK, South African, and Brazilian variants of SARS-CoV-2; An in silico perspective. Biochemical and Biophysical Research Communications. 2021;562:89 [Crossref]
13- S, Kumari D, Ranjan P, Chakraborty T. A computational study of potential therapeutics for COVID-19 invoking conceptual density functional theory. Struct Chem. 2022;33(6):2195 [Crossref]
14- Pourseif M, Masoudi-Sobhanzadeh Y, Azari E, Parvizpour S, Barar J, Ansari R, Omidi Y. Self-amplifying mRNA vaccines: Mode of action, design, development and optimization. Drug Discovery Today. 2022;27(11):103341 [Crossref]
15- Gamal H, Mostafa Shoeib E, Hajjaj A, Elsafy Abdelaziz Abdullah H, Elramy E, Ahmed Abd Ellah D, Mahmoud El-Sayed S, Fadl Khder M. Incorporating AI, in silico, and CRISPR technologies to uncover the potential of repurposed drugs in cancer therapy. RSC Pharm. 2025; [Crossref]
16- Safary A, Esalatmanesh K, Eftekharsadat A, Jafari Nakjavani M, Khabbazi A. Autoimmune inflammatory rheumatic diseases post-COVID‐19 vaccination. International Immunopharmacology. 2022;110:109061 [Crossref]
17- Rafiei F, Zeraati H, Abbasi K, Ghasemi J, Parsaeian M, Masoudi-Nejad A, Elofsson A. DeepTraSynergy: drug combinations using multimodal deep learning with transformers. 2023;39(8) [Crossref]
18- Speth R. An opinion on the impacts of COVID-19 worldwide. Bioimpacts. 2022;12(3):293 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of   
Follower of ICMJE
Permission: Creative Commons